Possible Reasons Why the Lp(a)HORIZON Lipoprotein(a)-Lowering Trial Failed to Demonstrate Improved Clinical Outcomes: Implications for Laboratory Medicine

作者
Eric S Kilpatrick
出处
期刊:The journal of applied laboratory medicine [Oxford University Press]
标识
DOI:10.1093/jalm/jfag172
摘要

The Lp(a)HORIZON trial aimed to determine whether lipoprotein(a) [Lp(a)] reduction using the drug pelacarsen could reduce cardiovascular (CV) risk in patients with both established cardiovascular disease (CVD) and an Lp(a) level ≥70 mg/dL (approximately 149 nmol/L), whose other CV risk factors were otherwise already treated optimally (1). On September 4, 2026, the topline results of the trial were announced stating that the trial failed to meet its primary endpoint of reducing the risk of CV events (2). This finding raises questions around the future of Lp(a) lowering as a target for improving CV outcomes and the benefit of measuring Lp(a) in this patient group. Given that Lp(a) resembles both LDL and plasminogen, it is understandable that it has gained attention as a CV risk factor or marker, but this interest has varied over the decades. In 1993, the negative findings in the large Physicians’ Health Study (3) were influential and lessened enthusiasm for Lp(a) at a time when the benefits of LDL cholesterol (LDL-C) lowering with statin treatment were being so compellingly demonstrated. This mood persisted despite a sample reanalysis of the Physicians’ Health Study, which showed more positive findings after using an Lp(a) assay that was relatively unaffected by apolipoprotein(a) size polymorphisms (4), thereby supporting the notion that Lp(a) concentrations be reported in relation to particle numbers (the molar unit being nmol/L) rather than as mass (mg/dL). Subsequently, Lp(a) underwent a sustained renaissance when Mendelian randomization studies consistently showed that the largely genetically determined concentrations of Lp(a), which remain similar throughout life, were most likely a causal risk factor rather than simply a risk marker for CVD risk (5). Other epidemiological studies, in contrast to the Physicians’ Health Study, consistently showed a clear association between high Lp(a) concentration and CV risk (6). As a consequence, many authoritative national and international guidelines now recommend measuring Lp(a) at least once in an adult’s life, with a view to using it as an additional factor to assess CV risk and, if raised, to inform cascade screening of family members. More recently, subcutaneously injectable treatments (antisense oligonucleotides and small interfering RNA), which target the mRNA coding for apolipoprotein(a), thereby preventing assembly of Lp(a) and so substantially lowering blood concentrations, have been developed (7). Pelacarsen, an antisense oligonucleotide, is the first of these agents to report outcome data (2). This placebo-controlled double-blind study tested pelacarsen against placebo in a 1:1 ratio in 8323 patients with Lp(a) concentrations ≥70 mg/dL who had existing optimally treated CVD (1). The 2 primary outcomes were to assess whether pelacarsen could reduce major adverse CV events (MACE) in the full study group and/or a subgroup with a screening Lp(a) ≥ 90 mg/dL. Pelacarsen was administered monthly, intended to produce an 80% reduction in circulating Lp(a) during a follow-up period of >2.5 years. The study was powered to detect a 20% reduction in its primary endpoints with >90% power (1). Given the promise that Lp(a) is such a potent risk factor for CVD, why might the Lp(a)HORIZON trial have been unable to show any benefit? Existing lipid-modifying agents influence Lp(a) concentrations, although not to the extent of the more recent injectable treatments. Agents with the largest reductions are the cholesteryl ester transfer protein inhibitors, with a 46% reduction from baseline, niacin (nicotinic acid) with a 37% reduction, and proprotein convertase subtilisin/kexin type 9 inhibitors showing a 29% reduction (8). However, niacin was withdrawn from sale as a lipid-lowering agent because trial data showed no improvement in CV outcomes (9), and cholesteryl ester transfer protein inhibitors have not been pursued commercially, beyond their LDL-C–lowering properties, because of both a lack of efficacy and safety concerns with some agents (10). In contrast, Proprotein convertase subtilisin/kexin type 9 inhibitors have consistently reduced MACE, although a meta-analysis of one of these agents showed Lp(a) reduction not to be associated with MACE independently of LDL-C reductions (11). Paradoxically, the classes of drugs with the best evidence base for reducing CV risk, namely the statins, ezetimibe and bempedoic acid, do not alter Lp(a) concentrations to the same degree (8). This disparity between the relative ability of these drugs to lower Lp(a) and their effectiveness at reducing CV risk has seldom been highlighted but may, in retrospect, have been a cautionary observation and seems of particular relevance following the outcome of Lp(a)HORIZON. In the 21st century, other credible markers of CV risk have unfortunately not fulfilled their promise. Among these are HDL cholesterol and plasma homocysteine. Cholesteryl ester transfer protein inhibitors addressed the hypothesis that raising HDL cholesterol by 30% to 133% could complement reducing LDL-C in lowering CV risk, but as previously mentioned, had minimal influence on CV outcomes (10). Enthusiasm for plasma homocysteine in the early 2000s, a test which also had strong epidemiological evidence extending to causality, initially followed a similar trajectory to that of Lp(a) in recent years (552 PubMed articles with “homocysteine” in their title in 2005 and 550 with Lp(a) or spelling variants in 2025). Intervention to reduce CV risk, this time with B vitamins, again proved unsuccessful (12). Treatments for hypertension, lipids and hyperglycemia can have an influence on their respective measured markers (blood pressure, LDL-C and glucose) within days or weeks of starting medication, but their subsequent impact on reducing CV risk is over different timescales, being within months to a year for antihypertensives, within a year to multiple years for lipid lowering, and multiple years to decades following improvements in glycemia. It is therefore speculation to suggest that lowering Lp(a), after a lifetime of exposure, would necessarily lead to any reduction in CV risk over a typical 5-year clinical trial or ever. Initial trials targeting LDL-C reduction often comprised patients with existing coronary or cerebrovascular disease (secondary prevention), as their high frequency of recurrent events allowed treatment effectiveness to be established with fewer patients over a shorter period. This population was also chosen for the Lp(a)HORIZON study, having a prior history of myocardial infarction, ischemic stroke, or symptomatic peripheral arterial disease (1). This apparently sensible choice may have inadvertently reduced the chance of demonstrating a treatment effect since the epidemiological CV risk gradient of Lp(a) seems steeper in subjects without CVD [hazard ratio, 1.10 for every 50 nmol/L (approximately 25 mg/dL) increase in Lp(a)] than in those with existing CVD (hazard ratio, 1.05) (13). This slope difference could demonstrate that optimal control of other CV risk factors leads to an attenuation in the residual risk explained by Lp(a). Added to this, epidemiological studies suggest Lp(a) is more closely associated with recurrent coronary artery disease than with ischemic stroke, and either event is more common in those with baseline coronary artery disease rather than previous stroke (13). In the Lp(a)HORIZON study, 9.8% of participants were recruited because they had a previous ischemic stroke, and the definition of MACE included fatal and nonfatal stroke (1). Each of these stroke patient inclusions may therefore have led to an apparent reduction in treatment effect. In contrast, other Lp(a)-lowering trials using different agents, such as olpasiran in the OCEAN(a) study, only include patients with previous coronary disease and have primary outcome measures influenced solely by coronary artery disease events (7). The fact that Lp(a)HORIZON recruited using a mass rather than molar Lp(a) assay could have unintentionally led to a cohort less likely to show treatment benefit. However, while these assays can categorize individuals quite differently, a recent reanalysis of Lp(a)HORIZON samples showed 97% agreement when categorizing patients using the 70 mg/dL trial threshold compared with using a 149 nmol/L molar cutoff (14). It suggests that assay units may not be a large factor in the trial failure. Had the Lp(a)HORIZON study shown a compelling beneficial effect of Lp(a) lowering on reducing CV risk, then it would likely have heralded a rapid expansion of laboratory requests [from its current test prevalence of approximately 0.1% in a US population (15)] to include most individuals with established CVD and for monitoring Lp(a) treatment response. There would also have been a further incentive to screen family members for high values. However, a single negative trial announcement does not mean increased demand will never materialize. For instance, it is not yet known if there was any signal of benefit to Lp(a) lowering in the trial just short of statistical significance, rather than there being completely no sign of CVD reduction. There are also 3 other Lp(a) secondary prevention intervention studies scheduled to report in the next 5 years (7), 2 of which use treatments that can lower Lp(a) concentrations more than pelacarsen. With different study designs and agents that can reduce Lp(a) further, they may be more likely to show a treatment benefit. It is also possible that it is the primary prevention population (without existing CVD) who might benefit most from Lp(a) lowering given their steeper CV risk gradient, but outcome data for this group are unlikely until at least 2031. At the moment, it seems prudent to continue using Lp(a) testing as currently recommended. If subsequent studies do not show CV risk to be modifiable by lowering Lp(a), then it will be interesting to see whether the test continues to be used to help guide the decision to start or intensify more established CV treatments such as statins and antihypertensives. However, based on the frequency of requests for other CV risk markers with similar potential purposes, such as high-sensitivity C-reactive protein or plasma homocysteine, even this continued use might not be guaranteed. Nonstandard Abbreviations: Lp(a), lipoprotein(a); CV, cardiovascular; CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; MACE, major adverse cardiovascular events. Author Contributions: The corresponding author takes full responsibility that all authors on this publication have met the following required criteria of eligibility for authorship: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved. Nobody who qualifies for authorship has been omitted from the list. E.S. Kilpatrick (Conceptualization, Formal analysis [equal]) Authors’ Disclosures or Potential Conflicts of Interest: Upon manuscript submission, all authors completed the author disclosure form. Research Funding: None declared. Disclosures: E.S. Kilpatrick is a deputy editor for Clinical Chemistry (ADLM).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI6.2的应助被山茶采纳,获得10
刚刚
李子发布了新的文献求助10
刚刚
不想起名字完成签到,获得积分10
刚刚
研友_VZG7GZ的应助被zhao采纳,获得10
刚刚
周围完成签到,获得积分10
刚刚
青妤完成签到 ,获得积分10
1秒前
16完成签到,获得积分10
1秒前
muse完成签到,获得积分10
1秒前
1秒前
xutai完成签到,获得积分10
1秒前
Simon完成签到,获得积分10
1秒前
风吹麦浪的应助被安彩青采纳,获得10
1秒前
ElviraHuang完成签到 ,获得积分10
2秒前
xzw完成签到,获得积分10
2秒前
等待着冬日的飞雪完成签到,获得积分10
2秒前
2秒前
2秒前
天Q完成签到,获得积分10
3秒前
张大喵完成签到,获得积分10
3秒前
王一完成签到 ,获得积分10
3秒前
甜甜的小虾米完成签到,获得积分10
3秒前
3秒前
跳跃毒娘发布了新的文献求助10
3秒前
典雅的面包完成签到,获得积分10
3秒前
XIAOATAIA发布了新的文献求助10
3秒前
4秒前
王欣完成签到 ,获得积分10
4秒前
奋斗的向雪完成签到,获得积分10
4秒前
奋斗完成签到 ,获得积分10
4秒前
5秒前
tian完成签到 ,获得积分10
6秒前
绿雪芽发布了新的文献求助20
6秒前
zzq完成签到,获得积分10
6秒前
KYC完成签到,获得积分10
6秒前
星光完成签到,获得积分10
6秒前
liuyang发布了新的文献求助10
6秒前
顺心若之完成签到,获得积分10
6秒前
Tina完成签到,获得积分10
6秒前
雷欧奥特曼完成签到,获得积分10
7秒前
刘斗江完成签到,获得积分10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8152354
求助须知:如何正确求助?哪些是违规求助? 9549023
关于积分的说明 21690364
捐赠科研通 7740603
什么是DOI,文献DOI怎么找? 3425157
关于科研通互助平台的介绍 2550379
邀请新用户注册赠送积分活动 2468675